SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Phase 3 Trial of Sac-TMT Meets Overall Survival Endpoint

Merck said its Phase 3 trial of sac-TMT in advanced gastroesophageal cancer met the overall survival endpoint.

MRK

Related stories